📣 Try out the NEW Gateway to Research and let us know what you think.

We're looking for users to test the new service during August and September and share their feedback. Express your interest by completing this short form.

Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis. (2022)

First Author: Harrison CN
Attributed to:  Unravelling biological heterogeneity in neoplastic myeloproliferative stem cells funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.2217/fon-2022-0484

PubMed Identifier: 35950489

Publication URI: http://europepmc.org/abstract/MED/35950489

Type: Journal Article/Review

Volume: 18

Parent Publication: Future oncology (London, England)

Issue: 27

ISSN: 1479-6694